While the ICR serves as an enhancer to improve the anti-tumour activity of CAR T-cell therapy, our anti-TNF CAR has the unique capability of redirecting macrophage phenotype and function, thereby reversing inflammation in acute and chronic diseases. Here, TNF is linked to neoplasm.